: A randomized, placebo-controlled trial of the safety and efficacy of tecovirimat for the treatment of patients with monkeypox virus disease

NIH RePORTER · NIH · N01 · $9,824,009 · view on reporter.nih.gov ↗

Abstract

The funding supports a clinical trial to identify effective treatments for monkeypox virus disease. Monkeypox virus is a re-emerging pathogen that causes monkeypox virus disease, a disease of epidemic potential that causes significant morbidity and can result in death. Human monkeypox cases have been increasing in sub-Saharan Africa since 2000 and sporadic outbreaks outside of Africa have occurred, with cases in the US and the UK in 2021. The similarity between MPXV and the variola virus, coupled with concerns about the potential of the variola virus as a potential bioterrorism agent, have placed monkeypox treatments at the forefront of public health and scientific research agendas in many countries.

Key facts

NIH application ID
10506292
Project number
75N91019D00024-P00001-759102000025-5
Recipient
LEIDOS BIOMEDICAL RESEARCH, INC.
Principal Investigator
LORI DODD
Activity code
N01
Funding institute
NIH
Fiscal year
2021
Award amount
$9,824,009
Award type
Project period
2020-09-28 → 2025-09-27